Two antifibrotic medications — nintedanib and pirfenidone — were approved in the fall of 2014 for use in idiopathic pulmonary fibrosis. While these medications are not a cure, they have both been shown to slow the decline of lung function over time. Ongoing studies of other medications for IPF have shown initial promise, but need more research.
OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). OFEV is indicated for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. OFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, primarily occurring in older adults, limited to the lungs, and associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP).  It causes lung scarring, which, over time, results in reduced oxygen intake.
Once the diagnosis of idiopathic pulmonary fibrosis is confirmed in the patient, appropriate treatment measures are initiated. Treatment usually involves prescription drugs and corticosteroids, to decrease inflammation in the pulmonary tissues and significantly slow down scarring in the lungs.
Treatment . Although there's no way to reverse the scarring that has already occurred, certain treatments—including medication, pulmonary rehabilitation, and surgery—may help prevent further damage, ease symptoms, and improve quality of life for people with pulmonary fibrosis.
Medicine is not the only treatment against IPF. Learn how to implement natural therapies, good diet, exercise, and breathing habits into your daily regimes. Join us in the fight against idiopathic pulmonary fibrosis!
1. Introduction. Idiopathic pulmonary fibrosis (IPF), the most common form of idiopathic interstitial pneumonia, is a chronic, progressive, lung disease characterized by the irreversible loss of lung architecture and function [, , ].Although the course of the disease is variable, mortality is high with a median survival of 2–5 years from the time of diagnosis; the cause of death is most ...
Chemotherapy drugs: Cancer treatment drugs may lead to pulmonary fibrosis. These include bleomycin, carmustine, methotrexate, and alkylating drugs like cyclophosphamide or busulfan. Carmustine may be the most likely of those to lead to pulmonary fibrosis, and is often used to treat lymphomas, myelomas or brain tumors. Heart medications: An
Idiopathic pulmonary fibrosis or IPF is a lung disease with symptoms and signs that include shortness of breath, muscle pain, joint discomfort, weight loss, and fatigue. Treatment is directed toward managing the signs and symptoms of IPF. Causes, life expectancy, and support group information are provided.
Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung diseases (also known as ILD), which describes lung diseases that involve inflammation or scarring in the lung. The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough.